Terran Biosciences
Terran Biosciences is a biotech platform company dedicated to developing transformative therapeutics and technologies for patients with neurological and psychiatric diseases. Their portfolio includes late-stage therapies for schizophrenia, innovative psychedelic therapies, and AI-enabled imaging software. They aim to become a leader in neuroscience by leveraging their expertise in drug design, clinical development, and medical software.
Industries
Nr. of Employees
small (1-50)
Products
Prodrug combination of xanomeline and trospium (oral and long-acting formulations)
A combination of prodrugs designed to overcome PK and physicochemical limitations of xanomeline and trospium to enable once-daily oral dosing and long-acting intramuscular injections.
Extended-release alpha-2 adrenergic antagonist formulation
An enantiomerically pure extended-release formulation of an alpha-2 adrenergic receptor antagonist intended for once-daily dosing, previously tested in late-stage clinical studies.
Selective serotonin 2A receptor antagonist programs
Late-stage 5-HT2A receptor antagonist assets under development for neuropsychiatric indications and for combination use with psychedelic therapies to modulate hallucinations and duration.
Psychedelic and empathogen compound development and supply
Development of novel psychedelic and empathogen chemistries (including oral prodrugs, long-acting forms, non-hallucinogenic psychoplastogens) and GMP manufacturing and supply of these compounds for research and clinical use.
Cloud-based neuromelanin MRI analysis software (FDA-cleared)
A cloud software platform for automated analysis of neuromelanin-sensitive MRI scans, intended to support neuroradiologist interpretation and provide diagnostic adjunctive information.
Prodrug combination of xanomeline and trospium (oral and long-acting formulations)
A combination of prodrugs designed to overcome PK and physicochemical limitations of xanomeline and trospium to enable once-daily oral dosing and long-acting intramuscular injections.
Extended-release alpha-2 adrenergic antagonist formulation
An enantiomerically pure extended-release formulation of an alpha-2 adrenergic receptor antagonist intended for once-daily dosing, previously tested in late-stage clinical studies.
Selective serotonin 2A receptor antagonist programs
Late-stage 5-HT2A receptor antagonist assets under development for neuropsychiatric indications and for combination use with psychedelic therapies to modulate hallucinations and duration.
Psychedelic and empathogen compound development and supply
Development of novel psychedelic and empathogen chemistries (including oral prodrugs, long-acting forms, non-hallucinogenic psychoplastogens) and GMP manufacturing and supply of these compounds for research and clinical use.
Cloud-based neuromelanin MRI analysis software (FDA-cleared)
A cloud software platform for automated analysis of neuromelanin-sensitive MRI scans, intended to support neuroradiologist interpretation and provide diagnostic adjunctive information.
Services
Drug design and medicinal chemistry services
Small-molecule design, prodrug strategy development, synthetic route design, and candidate optimization for CNS therapeutics.
CMC and process chemistry development
Process chemistry, formulation development, analytical support, and GMP manufacturing for clinical and research supply of CNS and psychedelic compounds.
Preclinical testing and PK/PD studies
In vitro and in vivo pharmacology and PK testing to support candidate selection and regulatory filings.
AI-enabled neuromelanin MRI analysis (cloud SaMD)
Cloud-based software for automated analysis of neuromelanin-sensitive MRI with EMR integration and clinical reporting workflows.
Drug design and medicinal chemistry services
Small-molecule design, prodrug strategy development, synthetic route design, and candidate optimization for CNS therapeutics.
CMC and process chemistry development
Process chemistry, formulation development, analytical support, and GMP manufacturing for clinical and research supply of CNS and psychedelic compounds.
Preclinical testing and PK/PD studies
In vitro and in vivo pharmacology and PK testing to support candidate selection and regulatory filings.
AI-enabled neuromelanin MRI analysis (cloud SaMD)
Cloud-based software for automated analysis of neuromelanin-sensitive MRI with EMR integration and clinical reporting workflows.
Expertise Areas
- Neuroscience therapeutics development
- Psychedelic and empathogen therapeutic development
- Antipsychotic and CNS small-molecule development
- Prodrug and long-acting formulation development
Key Technologies
- Prodrug design and development
- Predictive PK/PK modeling and simulation
- Medicinal chemistry and high-throughput synthesis
- Solid-state chemistry (salts, co-crystals, polymorphs)